Navigation Links
DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs
Date:1/4/2012

GAITHERSBURG, Md., Jan. 4, 2012 /PRNewswire-iReach/ -- DFH Pharma, Inc., (DFH) a privately held specialty pharmaceutical company focused exclusively in the HIV-1 therapeutic space, announced today the selection of CiVentiChem, LLC to provide medicinal chemistry services to support DFH efforts to develop the next generation of HIV maturation inhibitor drugs. Maturation inhibitors are a novel class of antiretroviral drug candidates that inhibit HIV-1 replication by interfering with the maturation of the HIV-1 virus. 

The collaboration will allow DFH Pharma to expedite the discovery of 2nd generation maturation inhibitor drugs by utilizing CiVentiChem's extensive experience in the preparation and characterization of small molecule drug candidates. During 2012 DFH will work closely with CiVentiChem to extend recent successful efforts to discover new drug candidates with potent activity against all HIV strains, including those that proved resistant to the first-in-class maturation inhibitor, bevirimat. In addition to the preparation of new triterpene analogs, which form the basis for the current 2nd generation program, DFH plans to work with CiVentiChem to explore new chemical space with the goal of identifying additional classes of compounds with maturation inhibition activity.

"We are very excited to be working with CiVentiChem in the discovery of new 2nd generation HIV maturation inhibitors" said Dr. David Martin, DFH Pharma Chief Development Officer.  Dr. Martin continued, "The collaboration will allow DFH access to world-class medicinal chemists and help the Company to achieve its primary goal of returning this exciting class of HIV drug to the clinic".  Bhaskar Venepalli, Ph.D., President of CiVentiChem commented, "We are very pleased that DFH Pharma has selected CiVentiChem as its chemistry partner. We look forward to employing our va
'/>"/>

SOURCE DFH Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer ... VPHM).   As a result of the waiver, ... Shire expects to complete the tender offer on January 24, ... satisfaction of all of the remaining conditions to the tender ...
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... market research report is available in its ... Market & Forecast – Worldwide Analysis ... Insulin Pump Market Analysis ... in the market as insulin delivery systems ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/16/2014)... SAN ANTONIO, Texas (April 16, 2014) A team ... The University of Texas Health Science Center at San ... the structure of a protein that helps a common ... Candida albicans causes yeast infections, diaper rashes ... pathogen to infect humans. It can also cause a ...
(Date:4/15/2014)... Scientists have solved a decades-old medical mystery and ... to fight invasive fungal infections, which kill about 1.5 million ... mechanism of action of amphotericin, an antifungal drug that has ... though it is nearly as toxic to human cells as ... report of the new findings appears in Nature ...
(Date:4/14/2014)... Henry Ford Hospital reached a medical milestone April ... using a novel way to access the heart. ... the United States performing the unique procedure called ... temporarily connecting major blood vessels. , Northern Michigan ... transcaval procedure on July 3, 2013 when traditional ...
(Date:4/14/2014)... John DeLuca, PhD, and Yael Goverover, PhD, OT, have ... persons with multiple sclerosis (MS) perform everyday life tasks. ... Measure Everyday Life Functional Activity in Multiple Sclerosis" provides ... senior VP of Research & Training at Kessler Foundation. ... is a visiting scientist at Kessler Foundation. She was ...
(Date:4/14/2014)... FRANCISCO, Calif.--True North Therapeutics, Inc., announced today a ... the destruction of human red blood cells exposed ... of autoimmune hemolytic anemia (AIHA). The article entitled ... prevents complement activation induced by cold agglutinin disease ... Blood earlier this month. TNT003 is ...
Breaking Medicine News(10 mins):Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2
... multiple low-energy treatments, combined with a plasma skin regeneration ... appearance, in record healing time. These multiple treatments have ... reduced healing times. ,"Plasma is a unique ... atoms to form an ionized gas," the authors write ...
... 27,000 women adds support to the view that high cholesterol ... even in healthy women with no history of heart disease ... importance of cholesterol levels as a risk factor for stroke, ... are otherwise healthy,” said study author Tobias Kurth, MD, ScD, ...
... over the influence of scantily clad dolls on young minds, ... one important reason for the rise of eating disorders, they ... voiced apprehension regarding the hype created by the media about ... which are known for their hour glass figures and revealing ...
... found evidence that a genetic tendency toward suicide has ... on chromosome 2. The same has been implicated in ... ,“We’re hoping our findings will eventually lead to tests ... suicide,” says Virginia Willour, Ph.D., an assistant professor in ...
... in women years in advance of a medical diagnosis ... ,Epidemiologists at the University at Buffalo in New ... diabetes found in the blood, such as markers of ... are present early on in women who eventually progress ...
... Otolaryngology-Head & Neck Surgery, chronic dizziness may be attributed// to ... study investigated 345 men and women who had suffered dizziness ... the age group of 15 to 89. It was found ... kind of anxiety disorders like migraine or a serious brain ...
Cached Medicine News:Health News:Multiple Low-energy Plasma Skin Treatments Beneficial in Reducing Facial Wrinkles 2Health News:Study Links Attempted Suicide With Genetic Evidence 2Health News:Study Links Attempted Suicide With Genetic Evidence 3Health News:Diabetes Risk Factors Develop Earlier in Women Than Men 2
... accommodate a variety of applications across a ... DestinyPlus is suitable for any laboratory demanding ... a mixed-mode throughput exceeding 95 PT/aPTT/Fibrinogen per ... full range of chromogenics, the AMAX DestinyPlus ...
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
Medicine Products: